Clear validation from Phylogica's collaborators at Cambridge University...
Because newly discovered targets might eventually be hit with a variety of different classes of drug, including antibodies, peptides and conventional ‘small molecule’ drugs, the market for Phylogica’s services has been significantly expanded by this discovery.
and..
One of the most significant advances in the Phylomer® platform has been its validation as a very powerful tool for the discovery of new ‘targets’, which are the disease-associated proteins in cells that can be hit with drugs. The need to access new drug targets is growing as the market for drugs against easily tractable targets using conventional approaches becomes more competitive. In fact, all drugs ever discovered hit only about 300 different human target proteins from amongst thousands of proteins, which, if activated or inhibited, could have therapeutic effects. Encouragingly, current evidence suggests that newer approaches to drug discovery, including therapeutic Phylomer® peptides, can access a much larger pool of disease targets, whether inside or outside cells. Furthermore, as we have described in this report, cell-penetrating Phylomers can be used to transport therapeutic payloads into cells, thus accessing the intracellular space.
PYC Price at posting:
2.4¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)